• El.p@štas
  • Tai įdomu
    • Sveikinimai
    • Receptai
    • Pramogos
    • Forumas
  • Skelbimai
  • Politika
  • IT naujienos
Litas.Lt
Žinantiems pinigų ir laiko vertę
  • Verslas
    • Bankai ir Draudimas
    • Nekilnojamas Turtas
    • Marketingas
    • Investicijos
    • Verslas
    • Transportas
    • Mokesčių naujienos
    • Technologijos
    • Renginiai
    • Taupymo patarimai
  • Karjera
    • Darbas ir karjera
    • Studijos
  • Laisvalaikis
    • Buitis, Namai
    • Sportas
    • Kelionės
    • Laisvalaikis
    • Sveikata
    • Įvairenybės
    • Kriminalai
    • El.p@štas
    • » Paskelbk
    • Kontaktai
    • Prisijungti

RSS TV laidos, filmai

  • Greitųjų antigenų testų konkurse varžosi 43 tiekėjai
  • Seimo Pirmininkė reiškia užuojautą dėl architekto prof. Vytauto Brėdikio netekties
  • Įdomioji sostinės metų statistika ir rečiausi vardai – gimė Perkūnija, Gūsis

RSS Horoskopai

  • Dienos horoskopas 12 zodiako ženklų
  • Gėlių horoskopas moterims pagal gimimo datą
  • Kavos horoskopas
  • 2021 metų horoskopas visiems zodiako ženklams: kas mūsų laukia šiais metais?
  • 2021 metų horoskopas Žuvims

RSS IT naujienos

  • Lietuvių programuotojų sukurtas įrankis gelbėja gyvybes JAV
  • „Samsung“ pristatė „Galaxy Buds Pro“ ausines: ypatingas garsas kiekvienam gyvenimo momentui
  • „Samsung“ pristatė naujausią flagmanų „Galaxy S21“ seriją

AZD1222 vaccine met primary efficacy endpoint in preventing COVID-19

  • Two different dosing regimens demonstrated efficacy with one showing a better profile
  • No hospitalisations or severe cases of COVID-19 in participants treated with AZD1222

Positive high-level results from an interim analysis of clinical trials of AZD1222 in the UK and Brazil showed the vaccine was highly effective in preventing COVID-19, the primary endpoint, and no hospitalisations or severe cases of the disease were reported in participants receiving the vaccine. There were a total of 131 COVID-19 cases in the interim analysis.

One dosing regimen (n=2,741) showed vaccine efficacy of 90% when AZD1222 was given as a half dose, followed by a full dose at least one month apart, and another dosing regimen (n=8,895) showed 62% efficacy when given as two full doses at least one month apart. The combined analysis from both dosing regimens (n=11,636) resulted in an average efficacy of 70%. All results were statistically significant (p<=0.0001). More data will continue to accumulate and additional analysis will be conducted, refining the efficacy reading and establishing the duration of protection.

An independent Data Safety Monitoring Board determined that the analysis met its primary endpoint showing protection from COVID-19 occurring 14 days or more after receiving two doses of the vaccine. No serious safety events related to the vaccine have been confirmed. AZD1222 was well tolerated across both dosing regimens.

AstraZeneca will now immediately prepare regulatory submission of the data to authorities around the world that have a framework in place for conditional or early approval. The Company will seek an Emergency Use Listing from the World Health Organization for an accelerated pathway to vaccine availability in low-income countries. In parallel, the full analysis of the interim results is being submitted for publication in a peer-reviewed journal.

Professor Andrew Pollard, Chief Investigator of the Oxford Vaccine Trial at Oxford, said: “These findings show that we have an effective vaccine that will save many lives. Excitingly, we’ve found that one of our dosing regimens may be around 90% effective and if this dosing regime is used, more people could be vaccinated with planned vaccine supply. Today’s announcement is only possible thanks to the many volunteers in our trial, and the hard working and talented team of researchers based around the world.”

Pascal Soriot, Chief Executive Officer, said: “Today marks an important milestone in our fight against the pandemic. This vaccine’s efficacy and safety confirm that it will be highly effective against COVID-19 and will have an immediate impact on this public health emergency. Furthermore, the vaccine’s simple supply chain and our no-profit pledge and commitment to broad, equitable and timely access means it will be affordable and globally available, supplying hundreds of millions of doses on approval.”

The pooled analysis included data from the COV002 Phase II/III trial in the UK and COV003 Phase III trial in Brazil. Over 23,000 participants are being assessed following two doses of either a half-dose/full-dose regimen or a regimen of two full doses of AZD1222 or a comparator, meningococcal conjugate vaccine called MenACWY or saline. The global trials are evaluating participants aged 18 years or over from diverse racial and geographic groups who are healthy or have stable underlying medical conditions.

Clinical trials are also being conducted in the US, Japan, Russia, South Africa, Kenya and Latin America with planned trials in other European and Asian countries. In total, the Company expects to enrol up to 60,000 participants globally.

The Company is making rapid progress in manufacturing with a capacity of up to 3 billion doses of the vaccine in 2021 on a rolling basis, pending regulatory approval. The vaccine can be stored, transported and handled at normal refrigerated conditions (2-8 degrees Celsius/ 36-46 degrees Fahrenheit) for at least six months and administered within existing healthcare settings.

AstraZeneca continues to engage with governments, multilateral organisations and collaborators around the world to ensure broad and equitable access to the vaccine at no profit for the duration of the pandemic.

COV002

COV002 is a single-blinded, multi-centre, randomised, controlled Phase II/III trial assessing the safety, efficacy and immunogenicity of AZD1222 in 12,390 participants in the UK. Trial participants to date are aged 18 years or over, who are healthy or have medically stable chronic diseases and are at increased risk for being exposed to the SARS-CoV-2 virus. Participants receive one or two intramuscular doses of a half dose (~2.5 x1010 viral particles) or full dose (~5×1010 viral particles) of AZD1222 or comparator, meningococcal vaccine MenACWY. Participants have blood samples drawn and clinical assessments for safety as well as immunogenicity at multiple timepoints up to one year post-vaccination. Suspected cases presenting with compatible symptoms were tested for virological confirmation by COVID-19 PCR. In addition, weekly swabbing are done for detection of infection and assessment of vaccine efficacy against infection.

COV003

COV003 is a single-blinded, multi-centre, randomised, controlled Phase III trial assessing the safety, efficacy, and immunogenicity of AZD1222 in 10,300 participants in Brazil. Trial participants to date are aged 18 years or over, who are healthy or have medically stable chronic diseases and are at increased risk for being exposed to the SARS-CoV-2 virus. Participants are randomised to receive two intramuscular doses of a full dose (~5×1010 viral particles) of AZD1222 or comparator, meningococcal vaccine MenACWY as first dose and a saline placebo as second dose. Participants have blood samples drawn and clinical assessments for safety as well as immunogenicity at multiple timepoints up to one year post-vaccination. Suspected cases presenting with compatible symptoms were tested for virological confirmation by COVID-19 PCR. 

AZD1222

AZD1222 was co-invented by the University of Oxford and its spin-out company, Vaccitech. It uses a replication-deficient chimpanzee viral vector based on a weakened version of a common cold virus (adenovirus) that causes infections in chimpanzees and contains the genetic material of the SARS-CoV-2 virus spike protein. After vaccination, the surface spike protein is produced, priming the immune system to attack the SARS-CoV-2 virus if it later infects the body.

AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.

Contacts

For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.

Pranešimą paskelbė: Greta Jankaitytė, UAB „Gravitas Partners“

Rekomenduojame
 
Bio Phyto Mild Facial Cleanser Veido prausiklis, 250 ml
 
TOMMY HILFIGER 15-39-01-5 Black 01 44
 
AUDIMAS Švelnaus mod.polo maršk.ilg.rank. 2021-571 Navy Blazer S
 
Este 83-28-05-8 Black 37
 
Camper Courb K300289 Blue 46
 
AUDIMAS Marginti medviln. maršk.ilg.rank. 2021-478 Mallard Green Printed S
2020 11 23   BNS Spaudos centras
  Sveikata
  • VU students repeat the success story by becoming the best team of this year’s iGEM competition

  • Naujas A. Kriščiūno darbas papuošė vilniečių pamėgtą rajoną

Leave a Reply

Cancel

You must be logged in to post a comment.

KurApsistoti? NT skelbimai eNuoma.lt Geros paslaugos Skelbti.lt MotoTurgus.lt

Draugai

Programa Centas
Smart SEO
Parduodami Domenai
Hey.lt - Interneto reitingai, lankomumo statistika, lankytoju skaitliukai

Temos

Bankai ir Draudimas Buitis, Namai Darbas ir karjera Investicijos IT naujienos Kelionės Korona virusas - Karantinas Laisvalaikis Marketingas Mokesčių naujienos Nekilnojamas Turtas Politika ir teisė Renginiai Sportas Studijos Sveikata Taupymo patarimai Technologijos Teisėsauga, kriminalai Transportas Verslas Įvairenybės

Rekomenduojame

  • cs 1.6 siųstis
  • Reklama internete | Seo paslaugos
  • filmai online
  • fs19 mods
  • Skalbimo mašinų remontas Vilniuje
  • Trumpalaikė buto nuoma
# > Jūsų nuoroda! < #

‹ › ×
    Copyright © 2000 - 2020Litas.Lt - Verslas, naujienos - Žinantiems pinigų ir laiko vertę, powered by WP
    This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish.Accept Read More
    Privacy & Cookies Policy

    Privacy Overview

    This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
    Necessary
    Always Enabled

    Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.

    Non-necessary

    Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.